- Report
- October 2024
- 194 Pages
Global
From €3280EUR$3,545USD£2,758GBP
€3644EUR$3,939USD£3,065GBP
- Report
- April 2025
- 200 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Report
- April 2025
- 200 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Report
- February 2025
- 200 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Report
- October 2024
- 210 Pages
Global
From €7354EUR$7,950USD£6,185GBP
- Drug Pipelines
- April 2025
- 450 Pages
Global
From €4625EUR$5,000USD£3,890GBP
- Report
- May 2023
- 180 Pages
Global
From €5504EUR$5,950USD£4,629GBP
- Report
- May 2024
- 128 Pages
Global
From €6012EUR$6,499USD£5,056GBP
- Report
- May 2024
- 130 Pages
Global
From €6012EUR$6,499USD£5,056GBP
- Report
- November 2023
- 30 Pages
Global
From €2544EUR$2,750USD£2,139GBP
- Report
- April 2023
- 114 Pages
Global
From €4394EUR$4,750USD£3,695GBP
- Report
- January 2024
- 95 Pages
United States
€3238EUR$3,500USD£2,723GBP
- Report
- May 2025
- 50 Pages
Global
From €2451EUR$2,650USD£2,062GBP

Tizanidine is a centrally-acting muscle relaxant used to treat spasticity, a condition characterized by muscle stiffness and spasms. It is a short-acting drug, meaning it is taken as needed to relieve spasticity symptoms. Tizanidine works by blocking nerve impulses that cause muscles to contract. It is available in both oral and intramuscular forms.
Tizanidine is used to treat a variety of conditions, including multiple sclerosis, spinal cord injury, cerebral palsy, and stroke. It is also used to treat muscle spasms caused by certain medications, such as baclofen and dantrolene. It is generally well-tolerated, with few side effects.
The tizanidine market is a small but growing segment of the central nervous system drugs market. It is used to treat a variety of conditions, and is generally well-tolerated with few side effects. As such, it is becoming increasingly popular as a treatment option for spasticity.
Some companies in the tizanidine market include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more